Zandra Klippel

1.1k total citations · 1 hit paper
34 papers, 790 citations indexed

About

Zandra Klippel is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Zandra Klippel has authored 34 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 17 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in Zandra Klippel's work include Multiple Myeloma Research and Treatments (17 papers), Neutropenia and Cancer Infections (14 papers) and Blood disorders and treatments (9 papers). Zandra Klippel is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Neutropenia and Cancer Infections (14 papers) and Blood disorders and treatments (9 papers). Zandra Klippel collaborates with scholars based in United States, France and Greece. Zandra Klippel's co-authors include Meletios Α. Dimopoulos, Anita Zahlten‐Kumeli, Saad Z. Usmani, David S. Siegel, María‐Victoria Mateos, Katja Weisel, Hui Yang, Ola Landgren, Xavier Leleu and Hang Quach and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Zandra Klippel

31 papers receiving 771 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

2020 289 citations Meletios Α. Dimopoulos, Hang Quach et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zandra Klippel United States	14	523	505	436	71	64	34	790
Ghulam Rehman Mohyuddin United States	13	342 0.7×	317 0.6×	226 0.5×	35 0.5×	42 0.7×	129	629
Adam Waxman United States	12	534 1.0×	470 0.9×	422 1.0×	30 0.4×	150 2.3×	32	935
Philippe Rodon France	9	483 0.9×	356 0.7×	433 1.0×	25 0.4×	30 0.5×	29	698
Niels Frost Andersen Denmark	17	371 0.7×	294 0.6×	425 1.0×	13 0.2×	105 1.6×	42	756
Bradley Augustson Australia	11	502 1.0×	312 0.6×	282 0.6×	18 0.3×	85 1.3×	43	684
Howard R. Terebelo United States	14	473 0.9×	309 0.6×	312 0.7×	16 0.2×	93 1.5×	74	716
Nicole A. Carreau United States	9	410 0.8×	159 0.3×	157 0.4×	41 0.6×	73 1.1×	12	677
Anne‐Marie Stoppa France	19	1.2k 2.2×	592 1.2×	756 1.7×	34 0.5×	216 3.4×	54	1.4k
S Kulkarni United Kingdom	18	692 1.3×	334 0.7×	256 0.6×	20 0.3×	129 2.0×	32	810
Pamela Bartels United States	7	454 0.9×	198 0.4×	194 0.4×	29 0.4×	199 3.1×	10	740

Countries citing papers authored by Zandra Klippel

Since Specialization

Citations

This map shows the geographic impact of Zandra Klippel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zandra Klippel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zandra Klippel more than expected).

Fields of papers citing papers by Zandra Klippel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zandra Klippel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zandra Klippel. The network helps show where Zandra Klippel may publish in the future.

Co-authorship network of co-authors of Zandra Klippel

This figure shows the co-authorship network connecting the top 25 collaborators of Zandra Klippel. A scholar is included among the top collaborators of Zandra Klippel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zandra Klippel. Zandra Klippel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209. 3 indexed citations

Perrot, Aurore, Paul G. Richardson, Joseph Mıkhael, et al.. (2023). P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES. HemaSphere. 7(S3). e3398301–e3398301. 1 indexed citations

Macé, Sandrine, et al.. (2023). Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186. Blood. 142(Supplement 1). 3360–3360. 1 indexed citations

Dimopoulos, Meletios Α., Hang Quach, María‐Victoria Mateos, et al.. (2020). Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. The Lancet. 396(10245). 186–197. 289 indexed citations breakdown →

Moreau, Philippe, Keith Stewart, Meletios Α. Dimopoulos, et al.. (2020). Once‐weekly (70 mg/m²) vs twice‐weekly (56 mg/m²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials. Cancer Medicine. 9(9). 2989–2996. 13 indexed citations

Shah, Jatin J., Saad Z. Usmani, Edward A. Stadtmauer, et al.. (2019). Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(9). 570–578.e1. 22 indexed citations

Façon, Thierry, Rubén Niesvizky, Katja Weisel, et al.. (2019). Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. Journal of Clinical Oncology. 37(15_suppl). 8028–8028. 3 indexed citations

Maxwell, Cathy, et al.. (2018). A Randomized, Single-Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim. Pain Management Nursing. 19(6). 693–706. 1 indexed citations

Li, Yanli, et al.. (2018). A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora. Journal of the National Comprehensive Cancer Network. 16(10). 1201–1208. 12 indexed citations

10.

Dale, David C., Jeffrey Crawford, Zandra Klippel, et al.. (2017). A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Supportive Care in Cancer. 26(1). 7–20. 58 indexed citations

11.

Façon, Thierry, Jae Hoon Lee, Philippe Moreau, et al.. (2017). Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 17(1). e26–e27. 30 indexed citations

12.

Li, Yanli, et al.. (2016). Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemotherapy and Pharmacology. 77(4). 703–712. 31 indexed citations

13.

Nordstrom, Beth, Jason C. Simeone, Karen G. Malley, et al.. (2016). Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer. Frontiers in Oncology. 6. 18–18. 25 indexed citations

14.

Li, Yanli, et al.. (2016). Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Supportive Care in Cancer. 24(10). 4377–4383. 34 indexed citations

15.

Cowan, Andrew J., Zandra Klippel, Philip A. Stevenson, et al.. (2016). Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid. 23(4). 254–259. 5 indexed citations

16.

Pintér, Tamás, Zandra Klippel, Alvydas Česas, et al.. (2016). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical Colorectal Cancer. 16(2). 103–114.e3. 21 indexed citations

17.

Klippel, Zandra, et al.. (2016). Evaluating the appropriateness of granulocyte colony-stimulating factor (G-CSF) use in patients (pts) receiving myelosuppressive chemotherapy by febrile neutropenia (FN) risk level.. Journal of Clinical Oncology. 34(15_suppl). e21691–e21691.

18.

Linenberger, Michael, Leona Holmberg, Pamela S. Becker, et al.. (2015). Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy. Bone Marrow Transplantation. 50(5). 663–667. 11 indexed citations

19.

Klippel, Zandra, Jeffrey Chou, Andrea Towlerton, et al.. (2014). Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Therapy. 21(3). 337–342. 30 indexed citations

20.

Klippel, Zandra, Jeffrey Chou, Andrea Towlerton, et al.. (2013). Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape. Blood. 122(21). 4205–4205.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact